Lead Programs

Chronic Kidney Disease (CKD)
Cytochroma Inc. is committed to building a product portfolio of unique Vitamin D therapies that advance the care of patients with Vitamin D insufficiency and Secondary Hyperparathyroidism in Chronic Kidney Disease (CKD).

• CTAP101 Capsules
  Vitamin D prohormone for the treatment of Vitamin D insufficiency in patients with Stage 3 or 4 CKD by restoring serum total Vitamin D prohormone concentrations to adequate levels (> 30 ng.mL).
  (CLICK HERE for more information on our Vitamin D Insufficiency Program)
• CTAP201 Capsules and Injection
  Active Vitamin D hormone for the treatment of Secondary Hyperparathyroidism in patients with Stages 3 through 5 CKD.
• CTA018 Injection (more information for CTA018 injection)
  Dual mechanism Vitamin D Receptor agonist and CYP24 inhibitor for the treatment of Secondary Hyperparathyroidism in patients with Stage 5 CKD.
  (CLICK HERE for more information on our Secondary Hyperparathyroidism Program)

Other Product Candidates

Chronic Kidney Disease (CKD)
Clinical applications include Vitamin D insufficiency and Secondary Hyperparathyroidism in Chronic Kidney Disease (CKD).

• CTAP001 Capsules
  Proprietary Vitamin D Product for the treatment of Vitamin D insufficiency for both the prescription and over-the-counter markets.
• CTAA101Capsules and CTAA102 Capsules
  CTAA101 Capsules and CTAA102 Capsules for Hyperphosphatemia in CKD. Novel, orally administered antibody-based approaches for the treatment of Hyperphosphatemia in patients with CKD.

Cancer
Clinical applications include prostate cancer.

• CTA002 Capsules and Injection (more information)
  Vitamin D analog for the treatment of cancer
• (CLICK HERE for more information on our Cancer Program)